Our Company

Aspiring to be the global leader in DDR-targeted cancer therapies

Our Pipeline

Pioneering the development of therapeutics to modulate DNA Damage Response

Our Science

Revolutionizing the future of cancer therapy

our clinical trials

Empowering novel cancer treatment options

Investors & Media

Achieving success through high standards of performance and conduct